These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Diagnosis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Concepts. Papatheodoridi M; Cholongitas E Curr Pharm Des; 2018; 24(38):4574-4586. PubMed ID: 30652642 [TBL] [Abstract][Full Text] [Related]
10. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. Vilar-Gomez E; Chalasani N J Hepatol; 2018 Feb; 68(2):305-315. PubMed ID: 29154965 [TBL] [Abstract][Full Text] [Related]
11. Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Non-invasive tests are enough. Castera L Liver Int; 2018 Feb; 38 Suppl 1():67-70. PubMed ID: 29427494 [TBL] [Abstract][Full Text] [Related]
12. Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Otgonsuren M; Estep MJ; Hossain N; Younossi E; Frost S; Henry L; Hunt S; Fang Y; Goodman Z; Younossi ZM J Gastroenterol Hepatol; 2014 Dec; 29(12):2006-13. PubMed ID: 25039333 [TBL] [Abstract][Full Text] [Related]
13. Epidemiology and natural history of non-alcoholic fatty liver disease. Fazel Y; Koenig AB; Sayiner M; Goodman ZD; Younossi ZM Metabolism; 2016 Aug; 65(8):1017-25. PubMed ID: 26997539 [TBL] [Abstract][Full Text] [Related]
14. Advances in noninvasive methods for diagnosing nonalcoholic fatty liver disease. Shen FF; Lu LG J Dig Dis; 2016 Sep; 17(9):565-571. PubMed ID: 27429213 [TBL] [Abstract][Full Text] [Related]
15. Current status of fibrosis markers. Patel K; Shackel NA Curr Opin Gastroenterol; 2014 May; 30(3):253-9. PubMed ID: 24671009 [TBL] [Abstract][Full Text] [Related]
16. Measurements of serum procollagen-III peptide and M30 do not improve the diagnostic accuracy of transient elastography for the detection of hepatic fibrosis in patients with nonalcoholic fatty liver disease. Ergelen R; Akyuz U; Aydin Y; Eren F; Yilmaz Y Eur J Gastroenterol Hepatol; 2015 Jun; 27(6):667-71. PubMed ID: 25923941 [TBL] [Abstract][Full Text] [Related]
17. Non-invasive diagnosis of advanced fibrosis and cirrhosis. Sharma S; Khalili K; Nguyen GC World J Gastroenterol; 2014 Dec; 20(45):16820-30. PubMed ID: 25492996 [TBL] [Abstract][Full Text] [Related]
18. Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future. Fitzpatrick E; Dhawan A World J Gastroenterol; 2014 Aug; 20(31):10851-63. PubMed ID: 25152587 [TBL] [Abstract][Full Text] [Related]
19. Utility and cost evaluation of multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease. Eddowes PJ; McDonald N; Davies N; Semple SIK; Kendall TJ; Hodson J; Newsome PN; Flintham RB; Wesolowski R; Blake L; Duarte RV; Kelly CJ; Herlihy AH; Kelly MD; Olliff SP; Hübscher SG; Fallowfield JA; Hirschfield GM Aliment Pharmacol Ther; 2018 Mar; 47(5):631-644. PubMed ID: 29271504 [TBL] [Abstract][Full Text] [Related]
20. Editorial: Magnetic Resonance Elastography and Non-Alcoholic Fatty Liver Disease: Time for an Upgrade? Flores A; Asrani SK Am J Gastroenterol; 2016 Jul; 111(7):995-6. PubMed ID: 27356823 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]